NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$22.18 +0.55 (+2.54 %)
(As of 05/28/2018 05:42 AM ET)
Previous Close$21.63
Today's Range$21.55 - $22.18
52-Week Range$10.85 - $33.82
Volume13.24 million shs
Average Volume14.67 million shs
Market Capitalization$22.55 billion
P/E Ratio5.64
Dividend Yield1.95%
Beta0.67

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries logoTeva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TEVA
CUSIPN/A
Phone972-3926-7267

Debt

Debt-to-Equity Ratio1.80
Current Ratio1.00
Quick Ratio0.65

Price-To-Earnings

Trailing P/E Ratio5.64
Forward P/E Ratio9.05
P/E Growth1.81

Sales & Book Value

Annual Sales$22.39 billion
Price / Sales1.01
Cash Flow$6.2655 per share
Price / Cash3.54
Book Value$16.13 per share
Price / Book1.38

Profitability

EPS (Most Recent Fiscal Year)$3.93
Net Income$-16,265,000,000.00
Net Margins-72.36%
Return on Equity18.59%
Return on Assets5.01%

Miscellaneous

Employees51,792
Outstanding Shares1,016,880,000

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries announced a quarterly dividend on Thursday, November 2nd. Stockholders of record on Tuesday, November 28th will be paid a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.53%. The ex-dividend date of this dividend is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries (NYSE:TEVA) issued its earnings results on Thursday, May, 3rd. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.63 by $0.28. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.80 billion. Teva Pharmaceutical Industries had a negative net margin of 72.36% and a positive return on equity of 18.59%. The business's quarterly revenue was down 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.06 earnings per share. View Teva Pharmaceutical Industries' Earnings History.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Teva Pharmaceutical Industries.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY18 earnings guidance on Thursday, May, 3rd. The company provided EPS guidance of $2.40-2.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.42. The company issued revenue guidance of $18.5-19.0 billion, compared to the consensus revenue estimate of $18.62 billion.

What price target have analysts set for TEVA?

27 Wall Street analysts have issued 12-month price targets for Teva Pharmaceutical Industries' stock. Their predictions range from $11.00 to $41.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $20.0577 in the next twelve months. View Analyst Ratings for Teva Pharmaceutical Industries.

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
  • 1. According to Zacks Investment Research, "Teva beat estimates for both earnings and sales in the first quarter and also raised its 2018 outlook. Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Nonetheless, Teva has a new organizational structure in place, is closing plants, cutting down its generics portfolio, divesting non-core assets, eliminating low-value R&D projects, and aims to cut its global workforce by more than 25% over the next two years to revive growth. Its financial position seems more stable than before as it is regularly paying down debt. After declining sharply in 2017, Teva’s shares have also picked up this year. However, Teva has a long way to go before gaining stability and resumption of organic growth seems unlikely before 2019." (5/9/2018)
  • 2. Maxim Group analysts commented, "Teva reported a better than expected quarter at $5.5B in revenues versus consensus at $5.3B, but we note revenues were down sequentially (3Q17: $5.6B). Generics came in at $3.1B and higher margin specialty at $1.8B. Copaxone in particular outperformed expectations, generating $821M, which is 34% greater than the $611M expected by the street. The beat on revenues followed through to non-GAAP EPS, which was $0.93, above expectations of $0.77." (2/8/2018)
  • 3. Cantor Fitzgerald analysts commented, "This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs." (12/14/2017)

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a increase in short interest in May. As of May 15th, there was short interest totalling 53,599,101 shares, an increase of 0.3% from the April 30th total of 53,782,387 shares. Based on an average trading volume of 16,116,685 shares, the days-to-cover ratio is currently 3.3 days.

Who are some of Teva Pharmaceutical Industries' key competitors?

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Michael McClellan, Exec. VP & CFO (Age 47)
  • Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 60)
  • Mr. Mark Sabag, Exec. VP of Global HR (Age 47)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 56)
  • Mr. Kåre Schultz, Pres, Chief Exec. Officer & Director (Age 57)

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

Headlines about TEVA stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries earned a coverage optimism score of 0.18 on Accern's scale. They also gave news stories about the company an impact score of 46.85 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (7.19%), Polaris Capital Management LLC (0.97%), OppenheimerFunds Inc. (0.42%), Thornburg Investment Management Inc. (0.37%), Swiss National Bank (0.33%) and Barrow Hanley Mewhinney & Strauss LLC (0.28%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Mark Sabag, Michael James Mcclellan, Richard Daniell, Roberto Mignone and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, Schroder Investment Management Group, Psagot Investment House Ltd., Clal Insurance Enterprises Holdings Ltd, State of Wisconsin Investment Board, Bellevue Group AG and Sei Investments Co.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Mark Sabag, Michael James Mcclellan, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was bought by a variety of institutional investors in the last quarter, including Thornburg Investment Management Inc., Polaris Capital Management LLC, Caisse DE Depot ET Placement DU Quebec, OppenheimerFunds Inc., Susquehanna Fundamental Investments LLC, CIBC World Markets Inc., New York State Common Retirement Fund and Natixis. View Insider Buying and Selling for Teva Pharmaceutical Industries.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $22.18.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $22.55 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or $3.93 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]


MarketBeat Community Rating for Teva Pharmaceutical Industries (TEVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  976 (Vote Outperform)
Underperform Votes:  873 (Vote Underperform)
Total Votes:  1,849
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
27 Wall Street analysts have issued ratings and price targets for Teva Pharmaceutical Industries in the last 12 months. Their average twelve-month price target is $20.0577, suggesting that the stock has a possible downside of 9.57%. The high price target for TEVA is $41.00 and the low price target for TEVA is $11.00. There are currently 7 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.961.961.962.04
Ratings Breakdown: 7 Sell Rating(s)
14 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
7 Sell Rating(s)
14 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
7 Sell Rating(s)
15 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
16 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.0577$20.0192$21.1750$21.1304
Price Target Upside: 9.57% downside12.34% upside12.99% upside40.21% upside

Teva Pharmaceutical Industries (NYSE:TEVA) Consensus Price Target History

Price Target History for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2018BarclaysSet Price TargetEqual Weight ➝ Hold$13.00 ➝ $20.00MediumView Rating Details
5/17/2018Cantor FitzgeraldSet Price TargetHold$18.00LowView Rating Details
5/14/2018Credit Suisse GroupSet Price TargetBuy$23.00LowView Rating Details
5/7/2018OppenheimerReiterated RatingHoldLowView Rating Details
5/7/2018Morgan StanleyReiterated RatingEqual Weight ➝ Hold$18.00LowView Rating Details
5/3/2018Maxim GroupReiterated RatingHoldLowView Rating Details
4/22/2018Wells Fargo & CoSet Price TargetSell$17.00LowView Rating Details
4/20/2018MizuhoReiterated RatingBuy$27.00LowView Rating Details
3/26/2018Royal Bank of CanadaReiterated RatingHold$16.00LowView Rating Details
3/20/2018Jefferies GroupInitiated CoverageHold ➝ Hold$19.00MediumView Rating Details
2/9/2018Bank of AmericaLower Price TargetUnderperform ➝ Underperform$17.00 ➝ $16.00LowView Rating Details
2/9/2018Leerink SwannLower Price TargetUnderweight ➝ Underperform$17.00 ➝ $16.00HighView Rating Details
2/9/2018Deutsche BankLower Price TargetHold ➝ Hold$20.00 ➝ $18.00MediumView Rating Details
2/9/2018GabelliDowngradeBuy ➝ Hold$19.00MediumView Rating Details
2/9/2018Piper Jaffray CompaniesDowngradeNeutral ➝ Underweight$11.00MediumView Rating Details
2/2/2018BTIG ResearchDowngradeNeutral ➝ Sell$17.00LowView Rating Details
1/25/2018Susquehanna BancsharesReiterated RatingPositive ➝ Positive$22.00 ➝ $24.00MediumView Rating Details
1/11/2018Goldman Sachs GroupBoost Price TargetBuy$20.00 ➝ $25.00HighView Rating Details
1/4/2018CitigroupUpgradeNeutral ➝ Buy$24.00LowView Rating Details
12/18/2017UBSSet Price TargetHold$12.00 ➝ $20.00LowView Rating Details
12/12/2017GuggenheimInitiated CoverageNeutral ➝ Neutral$16.00HighView Rating Details
11/13/2017JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$11.48 ➝ $11.00N/AView Rating Details
10/25/2017Evercore ISISet Price TargetBuy$38.00N/AView Rating Details
10/4/2017CowenReiterated RatingMarket Perform$30.00 ➝ $18.00N/AView Rating Details
9/21/2017Sanford C. BernsteinLower Price TargetMkt Perform ➝ Market Perform$28.00 ➝ $20.00LowView Rating Details
9/6/2017JMP SecuritiesBoost Price TargetUnderperform$13.00 ➝ $14.00LowView Rating Details
8/3/2017CIBCReiterated RatingOutperform ➝ Market PerformHighView Rating Details
2/28/2017ArgusDowngradeBuy ➝ Hold$59.35 ➝ $31.90N/AView Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveN/AView Rating Details
(Data available from 5/28/2016 forward)

Earnings

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings History and Estimates Chart

Earnings by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Estimates

2018 EPS Consensus Estimate: $2.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.58$0.63$0.61
Q2 20183$0.52$0.68$0.60
Q3 20183$0.49$0.55$0.52
Q4 20183$0.37$0.51$0.46

Teva Pharmaceutical Industries (NYSE TEVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018        
5/3/20183/31/2018$0.63$0.91$4.7992 billion$5.0650 billionViewN/AView Earnings Details
2/8/2018Q4 17$0.77$0.91$5.2870 billion$5.4590 billionViewListenView Earnings Details
11/2/2017Q3 2017$1.03$0.95$5.6065 billion$5.61 billionViewN/AView Earnings Details
8/3/20176/30/2017$1.06$0.99$5.7168 billion$5.6860 billionViewListenView Earnings Details
5/11/2017Q1 17$1.06$1.06$5.6885 billion$5.63 billionViewN/AView Earnings Details
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.7132 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.0590 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
11/2/2010Q3 2010$1.27$1.30ViewN/AView Earnings Details
7/26/2010Q2 2010$1.04$1.08ViewN/AView Earnings Details
5/4/2010Q1 2010$0.89$0.92ViewN/AView Earnings Details
2/16/2010Q4 2009$0.95$0.94ViewN/AView Earnings Details
11/3/2009Q3 2009$0.88$0.89ViewN/AView Earnings Details
7/28/2009Q2 2009$0.80$0.83ViewN/AView Earnings Details
5/5/2009Q1 2009$0.67$0.72ViewN/AView Earnings Details
2/17/2009Q4 2008$0.73$0.76ViewN/AView Earnings Details
11/6/2008Q3 2008$0.69$0.72ViewN/AView Earnings Details
7/29/2008Q2 2008$0.64$0.65ViewN/AView Earnings Details
5/6/2008Q1 2008$0.63$0.64ViewN/AView Earnings Details
2/12/2008Q4 2007$0.66$0.69ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend Information

Teva Pharmaceutical Industries pays an annual dividend of $0.43 per share, with a dividend yield of 1.94%. TEVA's most recent quarterly dividend payment was Tuesday, December 12. Teva Pharmaceutical Industries pays out 10.94% of its earnings out as a dividend.
Most Recent Dividend:12/12/2017
Annual Dividend:$0.43
Dividend Yield:1.94%
Dividend Growth:-14.40% (3 Year Average)
Payout Ratio(s):10.94% (Trailing 12 Months of Earnings)
17.55% (Based on This Year's Estimates)
17.48% (Based on Next Year's Estimates)
6.86% (Based on Cash Flow)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/2/2017quarterly$0.08502.74%11/27/201711/28/201712/12/2017
8/7/2017quarterly$0.08501.83%8/25/20178/29/20179/14/2017
5/11/2017quarterly$0.344.28%6/1/20176/5/20176/22/2017
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.28902/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.32102.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.35302.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.34702.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.32603.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.32203.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.32208/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Teva Pharmaceutical Industries (NYSE TEVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.43%
Institutional Ownership Percentage: 64.73%
Insider Trading History for Teva Pharmaceutical Industries (NYSE:TEVA)
Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE TEVA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2018Roberto MignoneDirectorBuy750,000$19.24$14,430,000.00View SEC Filing  
3/19/2018Deborah A GriffinInsiderSell943$17.88$16,860.84View SEC Filing  
3/19/2018Michael James McclellanCFOSell287$17.88$5,131.56View SEC Filing  
3/19/2018Richard DaniellVPSell1,297$17.89$23,203.331,297View SEC Filing  
3/19/2018Sven DethlefsEVPSell571$17.88$10,209.485,016View SEC Filing  
3/5/2018Brendan P O'gradyEVPSell705$19.38$13,662.90View SEC Filing  
3/5/2018Deborah A GriffinInsiderSell773$19.38$14,980.74View SEC Filing  
3/5/2018Richard DaniellVPSell1,108$19.28$21,362.24View SEC Filing  
2/15/2018Mark SabagEVPSell5,050$19.68$99,384.0044,517View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Teva Pharmaceutical Industries (NYSE TEVA) News Headlines

Source:
DateHeadline
Zacks: Brokerages Expect Teva Pharmaceutical Industries (TEVA) Will Post Quarterly Sales of $4.72 BillionZacks: Brokerages Expect Teva Pharmaceutical Industries (TEVA) Will Post Quarterly Sales of $4.72 Billion
www.americanbankingnews.com - May 27 at 3:04 AM
UPDATE 2-Indias Sun Pharma warns U.S. pricing pressure to hit 2019 profitUPDATE 2-India's Sun Pharma warns U.S. pricing pressure to hit 2019 profit
www.reuters.com - May 25 at 6:10 PM
Major Pharma Short Sellers Grow More SelectiveMajor Pharma Short Sellers Grow More Selective
www.msn.com - May 25 at 6:10 PM
Teva Pharmaceutical Industries (TEVA) Expected to Post Earnings of $0.68 Per ShareTeva Pharmaceutical Industries (TEVA) Expected to Post Earnings of $0.68 Per Share
www.americanbankingnews.com - May 25 at 1:15 PM
FDA Confirms September Action Date for Tevas Migraine DrugFDA Confirms September Action Date for Teva's Migraine Drug
www.msn.com - May 25 at 8:04 AM
Global Erythropoietin (EPO) Drugs Market Growth Opportunities: Teva Pharmaceutical Industries Ltd, Pfizer IncGlobal Erythropoietin (EPO) Drugs Market Growth Opportunities: Teva Pharmaceutical Industries Ltd, Pfizer Inc
www.marketwatch.com - May 25 at 8:04 AM
Teva Pharmaceutical Industries (TEVA) PT Raised to $20.00Teva Pharmaceutical Industries (TEVA) PT Raised to $20.00
www.americanbankingnews.com - May 24 at 2:07 PM
TXMD Awaits Big Day Next Week, TEVA Faces FDA In Sep., ESPR On WatchTXMD Awaits Big Day Next Week, TEVA Faces FDA In Sep., ESPR On Watch
www.nasdaq.com - May 24 at 8:04 AM
Teva hopes to launch migraine drug as soon as SeptemberTeva hopes to launch migraine drug as soon as September
www.reuters.com - May 24 at 8:04 AM
Cramer's lightning round: I don't have a thesis for Blue Apron, so don't buyCramer's lightning round: I don't have a thesis for Blue Apron, so don't buy
finance.yahoo.com - May 24 at 8:04 AM
BRIEF-Teva Confirms September PDUFA Date For FremanezumabBRIEF-Teva Confirms September PDUFA Date For Fremanezumab
www.reuters.com - May 23 at 5:47 PM
Teva Pharma (TEVA) Fremanezumab PDUFA Date Extended Until SeptemberTeva Pharma (TEVA) Fremanezumab PDUFA Date Extended Until September
www.streetinsider.com - May 23 at 5:47 PM
Teva Confirms September PDUFA Date for FremanezumabTeva Confirms September PDUFA Date for Fremanezumab
finance.yahoo.com - May 23 at 8:07 AM
Bile Duct Cancer Market Latest Industry Scenario, Trends, Share & Future Forecas 2017 – 2023Bile Duct Cancer Market Latest Industry Scenario, Trends, Share & Future Forecas 2017 – 2023
www.marketwatch.com - May 21 at 5:22 PM
Osgood-Schlatter Market – Overall Industry Analysis during forecast period 2017-2023Osgood-Schlatter Market – Overall Industry Analysis during forecast period 2017-2023
www.marketwatch.com - May 19 at 8:01 AM
Parathyroid Disorders Market Trend, Segmentation And Industry Analysis Research Report 2018-2023Parathyroid Disorders Market Trend, Segmentation And Industry Analysis Research Report 2018-2023
www.marketwatch.com - May 19 at 8:01 AM
Cantor Fitzgerald Reiterates "$18.00" Price Target for Teva Pharmaceutical Industries (TEVA)Cantor Fitzgerald Reiterates "$18.00" Price Target for Teva Pharmaceutical Industries (TEVA)
www.americanbankingnews.com - May 18 at 4:17 PM
Buffett Gets Even Greedier With Teva Pharmaceuticals. Time to Buy?Buffett Gets Even Greedier With Teva Pharmaceuticals. Time to Buy?
finance.yahoo.com - May 18 at 8:10 AM
Free Stock Performance Review on Teva Pharma and Three Other Healthcare SectorFree Stock Performance Review on Teva Pharma and Three Other Healthcare Sector
finance.yahoo.com - May 18 at 8:10 AM
Warren Buffett Pushing More Cash To Equities; Big 5 Stocks Still At The TopWarren Buffett Pushing More Cash To Equities; 'Big 5' Stocks Still At The Top
finance.yahoo.com - May 17 at 8:03 AM
Teva’s Fiscal Guidance: Confidence in Its GrowthTeva’s Fiscal Guidance: Confidence in Its Growth
finance.yahoo.com - May 17 at 8:03 AM
Teva Shares Jump After Warren Buffett Doubles Stake in DrugmakerTeva Shares Jump After Warren Buffett Doubles Stake in Drugmaker
www.thestreet.com - May 16 at 6:00 PM
Teva Stock Higher After Buffetts BumpTeva Stock Higher After Buffett's Bump
www.msn.com - May 16 at 6:00 PM
Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase ItTeva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase It
investorplace.com - May 16 at 12:21 PM
Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase ItTeva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase It
investorplace.com - May 16 at 12:18 PM
Global Sleeping Aids Market Growth Opportunities: Teva Pharmaceutical Industries Ltd., Sanofi, Compumedics LtdGlobal Sleeping Aids Market Growth Opportunities: Teva Pharmaceutical Industries Ltd., Sanofi, Compumedics Ltd
www.marketwatch.com - May 16 at 8:01 AM
Buffett Buys More Apple and Teva Shares, Dumps IBMBuffett Buys More Apple and Teva Shares, Dumps IBM
finance.yahoo.com - May 16 at 8:01 AM
Here's What Warren Buffett Is Buying and SellingHere's What Warren Buffett Is Buying and Selling
finance.yahoo.com - May 16 at 8:01 AM
How Valeant Pharmaceuticals’ Branded Rx Segment Performed in 1Q18How Valeant Pharmaceuticals’ Branded Rx Segment Performed in 1Q18
finance.yahoo.com - May 16 at 8:01 AM
U.S. state attorneys general sue Purdue Pharma over opioid epidemicU.S. state attorneys general sue Purdue Pharma over opioid epidemic
www.msn.com - May 15 at 5:59 PM
Teva shares up 5% on Berkshires increased stakeTeva shares up 5% on Berkshire's increased stake
www.marketwatch.com - May 15 at 5:59 PM
Berkshire doubles Teva stake, adds to Apple, ends a newspaper betBerkshire doubles Teva stake, adds to Apple, ends a newspaper bet
finance.yahoo.com - May 15 at 5:59 PM
Buffett's company doubles investment in drugmaker TevaBuffett's company doubles investment in drugmaker Teva
finance.yahoo.com - May 15 at 5:59 PM
Credit Suisse Group Analysts Give Teva Pharmaceutical Industries (TEVA) a $23.00 Price TargetCredit Suisse Group Analysts Give Teva Pharmaceutical Industries (TEVA) a $23.00 Price Target
www.americanbankingnews.com - May 15 at 1:07 PM
Teva up 1% premarket on Perrigo stumble with generic ProAirTeva up 1% premarket on Perrigo stumble with generic ProAir
seekingalpha.com - May 15 at 8:06 AM
An Overview of Valeant Pharmaceuticals’ Performance in 1Q18An Overview of Valeant Pharmaceuticals’ Performance in 1Q18
finance.yahoo.com - May 15 at 8:06 AM
Teva’s Austedo Sales Continue to Gain Momentum in 2018Teva’s Austedo Sales Continue to Gain Momentum in 2018
finance.yahoo.com - May 15 at 8:06 AM
Generic Drugmakers See Some Relief But May Not Have a Remedy YetGeneric Drugmakers See Some Relief But May Not Have a Remedy Yet
www.bloomberg.com - May 14 at 5:31 PM
Wall Street Is More Optimistic on Amgens Next Blockbuster DrugWall Street Is More Optimistic on Amgen's Next Blockbuster Drug
www.bloomberg.com - May 14 at 5:31 PM
Teva: It Will Get WorseTeva: It Will Get Worse
seekingalpha.com - May 14 at 5:31 PM
Teva Pharmaceutical Industries (TEVA) Receives Consensus Recommendation of "Hold" from AnalystsTeva Pharmaceutical Industries (TEVA) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 14 at 5:31 PM
Active Pharmaceutical Ingredient (API) Market is Supposed to Reach US$ 219.00 Billion By 2023Active Pharmaceutical Ingredient (API) Market is Supposed to Reach US$ 219.00 Billion By 2023
www.marketwatch.com - May 14 at 8:06 AM
Teva’s Restructuring Plan Is on TrackTeva’s Restructuring Plan Is on Track
finance.yahoo.com - May 14 at 8:06 AM
Teva Pharmaceutical Industries (TEVA) Director Roberto Mignone Purchases 750,000 SharesTeva Pharmaceutical Industries (TEVA) Director Roberto Mignone Purchases 750,000 Shares
www.americanbankingnews.com - May 11 at 7:23 PM
BRIEF-Teva Canada Announces Launch Of Teva-Cyclosporine Ophthalmic EmulsionBRIEF-Teva Canada Announces Launch Of Teva-Cyclosporine Ophthalmic Emulsion
www.reuters.com - May 10 at 6:18 PM
Teva Pharmaceutical Industries to Post Q2 2018 Earnings of $0.68 Per Share, Oppenheimer Forecasts (TEVA)Teva Pharmaceutical Industries to Post Q2 2018 Earnings of $0.68 Per Share, Oppenheimer Forecasts (TEVA)
www.americanbankingnews.com - May 10 at 6:25 AM
Teva Pharmaceutical Industries (TEVA) Expected to Post Quarterly Sales of $4.71 BillionTeva Pharmaceutical Industries (TEVA) Expected to Post Quarterly Sales of $4.71 Billion
www.americanbankingnews.com - May 10 at 4:44 AM
Teva Pharmaceutical Industries (TEVA) Upgraded at Zacks Investment ResearchTeva Pharmaceutical Industries (TEVA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:59 PM
Teva: The Numbers Dont Tell The Whole StoryTeva: The Numbers Don't Tell The Whole Story
seekingalpha.com - May 9 at 5:53 PM
Warren Buffetts 10 Big Stock LosersWarren Buffett's 10 Big Stock Losers
finance.yahoo.com - May 8 at 5:56 PM

SEC Filings

Teva Pharmaceutical Industries (NYSE:TEVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Teva Pharmaceutical Industries (NYSE:TEVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Teva Pharmaceutical Industries (NYSE TEVA) Stock Chart for Monday, May, 28, 2018

Loading chart…

This page was last updated on 5/28/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.